麻豆传媒

Early phase III data cement case for novel IL-17A inhibitor

New treatment options on the horizon come into better focus

Improvement in pain and function lasted well after formal program ended

The name says it all, but progress appears to be coming

Numbers of patients, length of follow-up keep growing with no visible downside (yet)

Novel agent adds additional action in hopes of improving efficacy

Phase III results back potential competitor for pegloticase-methotrexate treatment

Novel agent targets CD40 ligand

Of three major prognostic tools, none hit the mark

New study finds marked risk reduction tied to drugs' urate-lowering effect

Stunning improvement for two patients with rare form of autoimmune myositis

Familiar biologic halts progression in high-risk patients with just a few painful joints

In separate studies, one old standby and one newer biologic appeared helpful

Latest indication for deucravacitinib seen as approvable for multiple rheumatologic conditions